Rademikibart for Asthma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment called Rademikibart for individuals with asthma who have type 2 inflammation, a specific immune response. The goal is to determine if Rademikibart can manage asthma symptoms more effectively than a placebo (a substance with no active drug). Participants must have had asthma for at least a year and currently use inhalers or other medications for asthma control. They should also have experienced at least one severe asthma attack requiring steroid treatment. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop your current medications, but it does require that you are already on certain asthma treatments. You should discuss your specific medications with the trial team to see if any changes are needed.
Is there any evidence suggesting that Rademikibart is likely to be safe for humans?
Research has shown that rademikibart may improve lung function and control asthma. One study found that patients experienced quick and lasting benefits over 24 weeks. Importantly, research indicates that rademikibart does not increase eosinophils (a type of white blood cell) in the blood, which can be a concern with some asthma treatments.
Although detailed safety information from earlier phases is not available, this is a Phase 2 trial, meaning rademikibart has already passed initial safety tests. These trials primarily focus on the treatment's effectiveness and continue to monitor safety. While some safety data exist, more will be collected during this phase.12345Why do researchers think this study treatment might be promising for asthma?
Rademikibart is unique because it targets a novel pathway in asthma management, potentially offering relief where traditional treatments like inhaled corticosteroids and bronchodilators fall short. Unlike these standard options, which primarily focus on reducing inflammation or relaxing airway muscles, Rademikibart may work by modulating specific immune responses that trigger asthma attacks. Researchers are excited about the possibility of Rademikibart providing more personalized and effective treatment options for patients who don't respond well to existing therapies.
What evidence suggests that Rademikibart might be an effective treatment for asthma?
Research has shown that Rademikibart, which participants in this trial may receive, greatly improves lung function and helps control asthma. Patients experienced quick and lasting improvements over 24 weeks of treatment. Studies found that both doses of Rademikibart improved lung function by Week 12. The treatment works quickly and may also be useful for other lung conditions like COPD, a long-term lung disease. Overall, evidence suggests Rademikibart could be effective for people with asthma and type 2 inflammation.12367
Are You a Good Fit for This Trial?
This trial is for adults and adolescents with asthma who've been on a steady asthma control regimen for at least 60 days, have had an exacerbation in the past year requiring steroids, and show certain levels of blood eosinophils. They must be currently experiencing an acute asthma attack needing urgent care.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive rademikibart or placebo as an add-on to standard therapy for acute asthma exacerbation
Follow-up
Participants are monitored for treatment failure, including hospital readmission or need for additional treatment
What Are the Treatments Tested in This Trial?
Interventions
- Rademikibart
Find a Clinic Near You
Who Is Running the Clinical Trial?
Connect Biopharm LLC
Lead Sponsor